Wedbush Predicts Xencor’s FY2025 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR) – Equities research analysts at Wedbush raised their FY2025 earnings estimates for shares of Xencor in a report released on Thursday, November 6th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($1.96) per share for the year, up from their previous forecast of ($2.43). Wedbush has a “Outperform” rating and a $26.00 price objective on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor’s Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.87) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.99) EPS, FY2026 earnings at ($3.73) EPS, FY2027 earnings at ($3.87) EPS and FY2028 earnings at ($4.21) EPS.

Several other analysts have also issued reports on the company. Cantor Fitzgerald upped their price objective on Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Barclays raised Xencor from an “underweight” rating to an “overweight” rating and raised their price target for the company from $6.00 to $23.00 in a report on Wednesday, October 29th. Bank of America cut shares of Xencor from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Royal Bank Of Canada increased their price objective on shares of Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Tuesday, October 14th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and an average price target of $24.63.

Xencor Price Performance

Xencor stock opened at $14.87 on Monday. The company’s 50-day moving average is $11.95 and its 200-day moving average is $9.73. The firm has a market capitalization of $1.06 billion, a PE ratio of -6.20 and a beta of 0.99. Xencor has a fifty-two week low of $6.92 and a fifty-two week high of $27.24.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.64. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The company had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $29.73 million. During the same quarter in the prior year, the business posted ($0.71) EPS. The business’s revenue was up 18.0% compared to the same quarter last year.

Institutional Investors Weigh In On Xencor

Large investors have recently added to or reduced their stakes in the stock. State of Wyoming bought a new position in Xencor during the 1st quarter worth $34,000. CWM LLC lifted its position in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 2,231 shares during the period. Hantz Financial Services Inc. grew its holdings in shares of Xencor by 209.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 2,156 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Xencor by 77.1% in the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 1,449 shares during the period. Finally, Farther Finance Advisors LLC bought a new position in shares of Xencor in the third quarter worth $44,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.